[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [ACTIVE] · [HEALTH]

2 clusters · 4 sources · 4 days · First seen · Last updated

ESMO 2026 oncology clinical data presentations

Overview

During the 2026 European Society for Medical Oncology (ESMO) Annual Meeting, several biotechnology and pharmaceutical companies presented new clinical trial data regarding cancer treatments.

Roche and Genentech reported Phase III results from the Krascendo 1 trial, indicating that the KRAS G12C inhibitor divarasib showed superiority over first-generation inhibitors in treating advanced G12C-mutated non-small cell lung cancer. Roche also shared patient-reported outcomes for giredestrant in early-stage breast cancer. Concurrently, Arcus Biosciences provided updates on casdatifan for kidney cancer efficacy.

Other presentations focused on antibody-drug conjugates (ADCs). Kelun-Biotech released Phase II results for sac-TMT (SKB264) combined with pembrolizumab for cisplatin-ineligible urothelial cancer, reporting an objective response rate of 68%. Additionally, Innovent Biologics presented Phase I data for its CDH17-targeted ADC, CM518D1, which showed a 33.3% objective response rate in patients with advanced colorectal cancer.

Entities

European Society for Medical Oncology · Kelun-Biotech · Akeso · sac-TMT · Roche

Timeline

  1. [HEALTH] 2 sources
    Biotech companies present new ADC clinical data at ESMO 2026

    At ESMO 2026, Kelun-Biotech and Akeso (via CM518D1) presented promising clinical data for new ADC therapies targeting urothelial and colorectal cancers.

  2. [HEALTH] 2 sources
    Roche and Arcus Biosciences announce new clinical data

    Roche will present Phase III data on lung and breast cancer treatments at ESMO 2026, while Arcus Biosciences shared new kidney cancer data for casdatifan.

Sources

finanzen.at · gznf.net · pingtungtimes.com.tw · seekingalpha.com